Preclinical Targeted α- and β<sup>−</sup>-Radionuclide Therapy in HER2-Positive Brain Metastasis Using Camelid Single-Domain Antibodies

Preclinical Targeted α- and β<sup>−</sup>-Radionuclide Therapy in HER2-Positive Brain Metastasis Using Camelid Single-Domain Antibodies

HER2-targeted therapies have drastically improved the outcome for breast cancer patients. However, when metastasis to the brain is involved, current strategies fail to hold up to the same promise. Camelid single-domain antibody-fragments (sdAbs) have been demonstrated to possess favorable properties...

Full description

Bibliographic Details
Main Authors: Janik Puttemans, Yana Dekempeneer, Jos L. Eersels, Heleen Hanssens, Pieterjan Debie, Marleen Keyaerts, Albert D. Windhorst, Frank van der Aa, Quentin Lecocq, Karine Breckpot, Alfred Morgenstern, Frank Bruchertseifer, Tony Lahoutte, Nick Devoogdt, Matthias D’Huyvetter
Format: Article
Language:English
Published: MDPI AG 2020-04-01
Series:Cancers
Subjects:
single-domain antibody fragment
targeted radionuclide therapy
brain metastasis
HER2
Online Access:https://www.mdpi.com/2072-6694/12/4/1017

Similar Items

Similar Items